Oxidative Stress Levels, JAK2V617F Mutational Status and Thrombotic Complications in Patients with Essential Thrombocythemia

被引:0
|
作者
Moisa, Cornel [1 ]
Gaman, Mihnea Alexandru [2 ]
Diaconu, Camelia Cristina [2 ,3 ]
Gaman, Amelia Maria [4 ,5 ]
机构
[1] Cty Emergency Hosp Slatina, Dept Haematol, 5 Crisan Str, Slatina 230008, Romania
[2] Carol Davila Univ Med & Pharm, 8 Eroii Sanit Blvd, Bucharest 050474, Romania
[3] Clin Emergency Hosp Bucharest, Internal Med Clin, 8 Calea Floreasca Str, Bucharest 014461, Romania
[4] Univ Med & Pharm Craiova, Dept Pathophysiol, 2 Petru Rares Str, Craiova 200349, Romania
[5] Filantropia City Hosp, Clin Haematol, 1 Filantropiei Str, Craiova 200143, Romania
来源
REVISTA DE CHIMIE | 2019年 / 70卷 / 08期
关键词
essential thrombocythemia; reactive oxygen species; total antioxidant capacity; JAK2V617F; thrombosis; TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; CALRETICULIN; ACTIVATION; PLATELET; INFLAMMATION; IMPACT; MPL;
D O I
暂无
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Essential thrombocythemia (ET) is a BCR-ABL1-negative myeloproliferative neoplasm associated with thrombotic and haemorrhagic complications. Reactive oxygen species (ROS) overexpression induces a growth advantage to JAK2V617F-positive clones and, in association with a higher number of immature platelets, leukocytosis, and additional cardiovascular risk factors, leads to an increased risk for thrombotic events. We evaluated oxidative stress by measuring ROS levels and the total antioxidant capacity (TAC) in 62 ET patients and investigated the relationship between oxidative stress, JAK2V617F mutational status and the development of thrombotic events. We found higher oxidative stress levels in JAK2V617F-positive vs. JAK2V617F-negative ET cases with no significant differences between homozygous and heterozygous genotypes. Increased ROS levels and thrombotic events were more frequent in ET patients with old age at diagnosis, higher haematocrit levels or leukocytosis.
引用
收藏
页码:2822 / 2825
页数:4
相关论文
共 50 条
  • [21] Comparison of the effects between MPL and JAK2V617F on thrombosis and peripheral blood cell counts in patients with essential thrombocythemia: a meta-analysis
    Yang, Erpeng
    Wang, Mingjing
    Wang, Ziqing
    Li, Yujin
    Wang, Xueying
    Ming, Jing
    Xiao, Haiyan
    Quan, Richeng
    Liu, Weiyi
    Hu, Xiaomei
    ANNALS OF HEMATOLOGY, 2021, 100 (11) : 2699 - 2706
  • [22] JAK2V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients
    Palandri, Francesca
    Ottaviani, Emanuela
    Salmi, Federica
    Catani, Lucia
    Polverelli, Nicola
    Fiacchini, Mauro
    Martinelli, Giovanni
    Baccarani, Michele
    Vianelli, Nicola
    LEUKEMIA & LYMPHOMA, 2009, 50 (02) : 247 - 253
  • [23] Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients
    Chim, C. S.
    Sim, J. P.
    Chan, C. C.
    Kho, B. C.
    Chan, J. C.
    Wong, L. G.
    Law, M.
    Liang, R.
    Kwong, Y. L.
    HEMATOLOGY, 2010, 15 (04) : 187 - 192
  • [24] Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers
    Trelinski, Jacek
    Wierzbowska, Agnieszka
    Krawczynska, Anna
    Sakowicz, Agata
    Pietrucha, Tadeusz
    Smolewski, Piotr
    Robak, Tadeusz
    Chojnowski, Krzysztof
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 91 (05) : 792 - 798
  • [25] Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status
    Trelinski, Jacek
    Wierzbowska, Agnieszka
    Krawczynska, Anna
    Sakowicz, Agata
    Pietrucha, Tadeusz
    Smolewski, Piotr
    Robak, Tadeusz
    Chojnowski, Krzysztof
    LEUKEMIA & LYMPHOMA, 2010, 51 (09) : 1727 - 1733
  • [26] Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia
    Abdelghani, Maroua
    Hammami, Haifa
    Zidi, Wiem
    Amouri, Hassiba
    Othmen, Hind Ben Hadj
    Farrah, Ahlem
    Menif, Samia
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2022, 36 (08)
  • [27] Significance of combined detection of JAK2V617F, MPL and CALR gene mutations in patients with essential thrombocythemia
    Ji, Liying
    Qian, Mengyao
    Wu, Nana
    Wu, Jianmin
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 13 (03) : 947 - 951
  • [28] Absence of FTL3 mutations in patients with JAK2V617F mutation negative essential thrombocythemia
    Medeiros, Bruno C.
    Zhang, Tong
    Lipton, Jeffrey H.
    Kamel-Reid, Suzanne
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (04) : 293 - 294
  • [29] Do we know more about essential thrombocythemia because of JAK2V617F?
    Harrison C.
    Current Hematologic Malignancy Reports, 2009, 4 (1) : 25 - 32
  • [30] The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients
    Pardanani, A.
    Lasho, T. L.
    Finke, C. M.
    Gangat, N.
    Wolanskyj, A. P.
    Hanson, C. A.
    Tefferi, A.
    LEUKEMIA, 2010, 24 (01) : 110 - 114